論文リスト

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2023年

  1. Masamoto Y, Shimura A, Honda A, Taoka K, Maki H, Kurokawa M.
    Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
    Ann Hematol. 2023 Jan;102(1):243-244.
  2. Oyama T, Matsuda K, Honda A, Maki H, Masamoto Y, Murakami D, Toya T, Sakurai M, Kataoka K, Doki N, Kurokawa M.
    Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
    Int J Hematol. 2023 Feb;117(2):260-268.
  3. Matsuda K, Oyama T, Maki H, Nakazaki K, Yasunaga M, Honda A, Masamoto Y, Kurokawa M.
    Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia.
    Intern Med. 2023 Aug 1;62(15):2181-2185.
  4. Oyama T, Taoka K, Chiba A, Masamoto Y, Ikemura M, Honda A, Maki H, Kurokawa M.
    Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
    Int J Hematol. 2023 Mar;117(3):463-467.
  5. Yoshida M, Morita K, Fukushima H, Jona M, Nishikawa M, Yatomi Y, Kishino Y, Iwasaki A, Ushiku T, Imadome KI, Honda A, Maki H, Kurokawa M.
    Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
    Int J Hematol. 2023 May;117(5):769-773.
  6. Yoshida M, Matsuda K, Endo K, Honda A, Maki H, Taoka K, Masamoto Y, Wakimoto Y, Jubishi D, Moriya K, Kurokawa M.
    Toxic shock like syndrome caused by Streptococcus agalactiae bacteremia during treatment for multiple myeloma.
    J Infect Chemother. 2023 Apr;29(4):407-409.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2022年

  1. Yokomizo T, Ideue T, Morino-Koga S, Tham CY, Sato T, Takeda N, Kubota Y, Kurokawa M, Komatsu N, Ogawa M, Araki K, Osato M, Suda T.
    Independent origins of fetal liver haematopoietic stem and progenitor cells.
    Nature. 2022 Sep;609(7928):779-784.
  2. Oyama T, Taoka K, Chiba A, Matsuda K, Maki H, Masamoto Y, Kurokawa M.
    Bing-Neel Syndrome Successfully Treated with Tirabrutinib.
    Intern Med. 2022 Dec 1;61(23):3575-3579.
  3. Masamoto Y, Shimura A, Kurokawa M.
    Reduced bendamustine for elderly patients with follicular lymphoma.
    Ann Hematol. 2022 Mar;101(3):713-715.
  4. Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, Yasunaga M, Sato S, Kurokawa M.
    Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.
    Int J Hematol. 2022 Sep;116(3):446-452.
  5. Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M.
    CAMK2G is identified as a novel therapeutic target for myelofibrosis.
    Blood Adv. 2022 Mar 8;6(5):1585-1597.
  6. Takano H, Yasunaga M, Yamazaki I, Nishikawa M, Masamoto Y, Shinozaki-Ushiku A, Kawakami M, Yatomi Y, Kurokawa M.
    Degenerated mitochondria in leukemic blast appeared as granules on May-Grunwald-Giemsa staining.
    Ann Hematol. 2022 May;101(5):1135-1136.
  7. Shull LC, Lencer ES, Kim HM, Goyama S, Kurokawa M, Costello JC, Jones K, Artinger KB.
    PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation.
    Development. 2022 Feb 15;149(4):dev200082.
  8. Shiroshita K, Kobayashi H, Watanuki S, Karigane D, Sorimachi Y, Fujita S, Tamaki S, Haraguchi M, Itokawa N, Aoyoama K, Koide S, Masamoto Y, Kobayashi K, Nakamura-Ishizu A, Kurokawa M, Iwama A, Okamoto S, Kataoka K, Takubo K.
    A culture platform to study quiescent hematopoietic stem cells following genome editing.
    Cell Rep Methods. 2022 Dec 5;2(12):100354.
  9. Higo T, Suzuki Y, Sato M, Koya J, Mizuno H, Miyauchi M, Masamoto Y, Kataoka K, Sumitomo Y, Tsuruta-Kishino T, Sato T, Kurokawa M.
    Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool.
    Exp Hematol. 2022 May;109:45-54.
  10. Murakami D, Maki H, Matsuda K, Masamoto Y, Suzuki F, Amemiya S, Osawa K, Hinata M, Ikemura M, Ushiku T, Kurokawa M.
    Cerebral toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission.
    J Infect Chemother. 2022 Feb;28(2):279-282.
  11. Ogawa E, Edamitsu T, Ohmori H, Kohu K, Kurokawa M, Kiyonari H, Satake M, Okuyama R.
    Transcription Factors Runx1 and Runx3 Suppress Keratin Expression in Undifferentiated Keratinocytes.
    Int J Mol Sci. 2022 Sep 2;23(17):10039.
  12. Kurihara Y, Mizuno H, Honda A, Shimura A, Fujioka Y, Maki H, Kurokawa M.
    CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.
    J Cell Mol Med. 2022 Feb;26(3):950-952.
  13. Hayashida H, Honda A, Hino T, Mizuno H, Toyama K, Kurokawa M.
    A case of thymoma showing significant tumor reduction after anti-thymocyte globulin.
    Gen Thorac Cardiovasc Surg. 2022 Jan;70(1):96-99.
  14. Murakami D, Matsuda K, Honda A, Masamoto Y, Kurokawa M.
    Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia.
    Int J Hematol. 2022 Oct;116(4):482-488.
  15. Fukui Y, Honda A, Takano H, Obo T, Mizuno H, Masamoto Y, Kurokawa M.
    Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma.
    J Clin Exp Hematop. 2022 Dec 28;62(4):217-221.
  16. Masamoto Y, Taoka K, Maki H, Kurokawa M.
    Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.
    Ann Hematol. 2022 Dec;101(12):2795-2797.
  17. Ebisawa K, Masamoto Y, Yagi K, Kurokawa M.
    A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.
    Ann Hematol. 2022 Nov;101(11):2551-2552.
  18. Hino T, Honda A, Shimura A, Masamoto Y, Kurokawa M.
    R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis.
    Int J Hematol. 2022 Feb;115(2):296-297.
  19. Ebisawa K, Honda A, Chiba A, Masamoto Y, Okazaki H, Kurokawa M.
    High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy.
    J Clin Apher. 2022 Feb;37(1):4-12.
  20. Kato K, Yabe H, Shimozawa N, Adachi S, Kurokawa M, Hashii Y, Sato A, Yoshida N, Kaga M, Onodera O, Kato S, Atsuta Y, Morio T.
    Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan.
    Pediatr Transplant. 2022 Feb;26(1):e14125.
  21. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, Katayama Y, Kurokawa M, Nakamae H, Yano S, Nawa Y, Kanda Y, Fukuda T, Atsuta Y, Kako S.
    Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Int J Hematol. 2022 Sep;116(3):393-400.
  22. Matsuda K, Jo T, Shimura A, Honda A, Taoka K, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, Kurokawa M.
    Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R-CHOP regimen: a nationwide real- world study in Japan.
    Br J Haematol. 2022 May;197(3):e37-e41.
  23. Oyama T, Matsuda K, Honda A, Yasunaga M, Nakazaki K, Maki H, Masamoto Y, Kurokawa M.
    Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2022 Dec;63(14):3497-3500.
  24. Sato M, Yasunaga M, Ohzu M, Toyama K, Nakazaki K, Nakahara F, Kubo T, Okura N, Abe O, Kurokawa M.
    Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
    Ann Hematol. 2022 May;101(5):1153-1155.
  25. Ito Y, Honda A, Kurokawa M.
    Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis.
    Blood Adv. 2022 Mar 8;6(5):1499-1511.
  26. Ito Y, Honda A, Kurokawa M.
    COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
    Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e691-e707.
  27. Miyashita H, Taoka K, Kume A, Ushiku A, Ushiku T, Toyama K, Kurokawa M.
    Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation.
    Ann Hematol. 2022 Nov;101(11):2477-2483.
  28. Murayama R, Oyama H, Abe-Doi M, Masamoto Y, Kashiwabara K, Tobe H, Komiyama C, Sanada H, Kurokawa M.
    Safety verification of a new peripheral intravenous catheter placed in the upper arm vein for administration of drugs with high irritant potential.
    Drug Discov Ther. 2022 Jul 20;16(3):128-134.
  29. Sato M, Honda A, Maki H, Toyama K, Yamaguchi R, Ikeda M, Moriya K, Kurokawa M.
    Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy.
    J Infect Chemother. 2022 Jan;28(1):91-94.
  30. A case of thymoma showing significant tumor reduction after anti-thymocyte globulin.
    Hayashida H, Honda A, Hino T, Mizuno H, Toyama K, Kurokawa M.
    Gen Thorac Cardiovasc Surg. 2022 Jan;70(1):96-99.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2021年

  1. Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment.
    Miyauchi M, Ito Y, Nakahara F, Hino T, Nakamura F, Iwasaki Y, Kawagoshi T, Koya J, Yoshimi A, Arai S, Kagoya Y, Kurokawa M.
    Blood. 2021 Dec 16;138(24):2555-2569.
  2. Monomorphic Epitheliotropic Intestinal T-cell Lymphoma Invades Brain.
    Morimoto A, Fujioka Y, Ushiku T, Kurokawa M.
    Intern Med. 2021 Mar 1;60(5):815-816.
  3. CD62L expression level determines the cell fate of myeloid progenitors.
    Ito Y, Nakahara F, Kagoya Y, Kurokawa M.
    Stem Cell Reports. 2021 Dec 14;16(12):2871-2886.
  4. Physical interaction between BAALC and DBN1 induces chemoresistance in leukemia.
    Maki H, Yoshimi A, Shimada T, Arai S, Morita K, Kamikubo Y, Ikegawa M, Kurokawa M.
    Exp Hematol. 2021 Feb;94:31-36.
  5. A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor.
    Sasaki K, Matsuda K, Miyauchi M, Honda A, Shimura A, Masamoto Y, Kurokawa M.
    Ann Hematol. 2021 May;100(5):1341-1343.
  6. Treatment of Secondary Immune Thrombocytopenia with Non-Hodgkin Lymphoma: A Case Report and Literature Review.
    Kurihara Y, Taoka K, Takagi E, Toyama K, Nakazaki K, Kurokawa M.
    Intern Med. 2021;60(10):1583-1588.
  7. Clinical Features and Prognostic Factors for Primary Anaplastic Large Cell Lymphoma of the Central Nervous System: A Systematic Review.
    Hirano Y, Miyawaki S, Tanaka S, Taoka K, Hongo H, Teranishi Y, Takami H, Takayanagi S, Kurokawa M, Saito N.
    Cancers (Basel). 2021 Aug 28;13(17):4358.
  8. Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
    Honda A, Koya J, Yoshimi A, Miyauchi M, Taoka K, Kataoka K, Arai S, Kurokawa M.
    Exp Hematol. 2021 Sep;101-102:42-48.e11.
  9. MECOM permits pancreatic acinar cell dedifferentiation avoiding cell death under stress conditions.
    Backx E, Wauters E, Baldan J, Van Bulck M, Michiels E, Heremans Y, De Paep DL, Kurokawa M, Goyama S, Bouwens L, Jacquemin P, Houbracken I, Rooman I.
    Cell Death Differ. 2021 Sep;28(9):2601-2615.
  10. Cerebral toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission.
    Murakami D, Maki H, Matsuda K, Masamoto Y, Suzuki F, Amemiya S, Osawa K, Hinata M, Ikemura M, Ushiku T, Kurokawa M.
    J Infect Chemother. 2022 Feb;28(2):279-282.
  11. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.
    Morishima S, Fukuda T, Doki N, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Bone Marrow Transplant. 2021 Mar;56(3):646-654.
  12. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease.
    Ebisawa K, Shimura A, Honda A, Masamoto Y, Nakahara F, Kurokawa M.
    Leuk Lymphoma. 2021 Mar;62(3):614-619.
  13. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation.
    Mizuno H, Koya J, Masamoto Y, Kagoya Y, Kurokawa M.
    Cancer Sci. 2021 Oct;112(10):4112-4126.
  14. Use of wide-spectrum antimicrobials with blood culture tests during chemotherapy as an accurate marker of febrile neutropenia in the DPC database: A validation study.
    Matsuda K, Ise M, Shimura A, Honda A, Masamoto Y, Jo T, Yasunaga H, Kurokawa M.
    J Infect Chemother. 2021 Oct;27(10):1541-1542.
  15. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.
    Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL.
    Haematologica. 2021 Nov 1;106(11):3004-3007.
  16. Severe cellulitis caused by Achromobacter xylosoxidans after allogeneic hematopoietic stem cell transplantation.
    Oyama Y, Yasunaga M, Honda A, Maki H, Masamoto Y, Kobayashi T, Wakabayashi Y, Okugawa S, Moriya K, Kurokawa M.
    J Infect Chemother. 2021 May;27(5):770-772.
  17. Immature platelet levels correlate with disease activity and predict treatment response of thrombocytopenia in lupus patients.
    Hanata N, Shoda H, Kono M, Komai T, Natsumoto B, Tsuchida Y, Tsuchiya H, Nagafuchi Y, Taoka K, Kurokawa M, Fujio K.
    Lupus. 2021 Oct;30(11):1764-1772.
  18. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
    Ise M, Matsuda K, Shimura A, Masamoto Y, Kurokawa M.
    Int J Hematol. 2021 Jun;113(6):823-831.
  19. Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: A nation-wide analysis in Japan.
    Matsuda K, Jo T, Miyauchi M, Toyama K, Nakazaki K, Matsui H, Fushimi K, Yasunaga H, Kurokawa M.
    J Infect Chemother. 2021 Aug;27(8):1151-1155.
  20. Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
    Takezaki T, Nakazaki K, Toyama K, Matsuda K, Kogure Y, Chiba A, Nakamura F, Honda A, Kurokawa M.
    Hematol Oncol. 2021 Oct;39(4):465-472.
  21. Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Matsuda K, Jo T, Toyama K, Nakazaki K, Matsui H, Fushimi K, Yasunaga H, Kurokawa M.
    Ann Hematol. 2021 Oct;100(10):2613-2619.
  22. Serial assessments of anterior pituitary hormones in a case of mixed histiocytosis representing Langerhans cell histiocytosis overlapping with Erdheim-Chester disease.
    Ito K, Ito J, Yamamoto Y, Nakajima R, Fujii M, Katakura Y, Muramatsu A, Takayashiki N, Toyama K, Kurokawa M, Yagyu H.
    Endocrinol Diabetes Metab Case Rep. 2021 May 1;2021:21-0030.
  23. Rapidly progressing blastic plasmacytoid dendritic cell neoplasm causing diffuse skin thickening: A case report with sequential computed tomography examinations.
    Yoshioka K, Kurokawa R, Amemiya S, Koyamaa H, Matsuda K, Honda A, Kurokawa M, Shinozaki-Ushiku A, Abe O.
    Radiol Case Rep. 2021 Aug 3;16(10):2929-2933.
  24. Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome.
    Yasunaga M, Yasuda Y, Honda A, Maki H, Toyama K, Masamoto Y, Bujo C, Amiya E, Hatano M, Ono M, Komuro I, Kurokawa M.
    Ann Hematol. 2021 Apr;100(4):1097-1100.
  25. A case of transplantation-associated thrombotic microangiopathy with autopsy-proven fatal myocardial ischemia after allogeneic hematopoietic stem cell transplantation.
    Sasaki K, Honda A, Shinozaki-Ushiku A, Fujioka Y, Maki H, Toyama K, UshikuT, and Kurokawa M.
    Ann Hematol. 2021 Jun;100(6):1621-1622.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2020年

  1. Posterior Reversible Encephalopathy Syndrome Concurrent with Human Herpesvirus-6B Encephalitis after Allogeneic Hematopoietic Stem Cell Transplantation.
    Ito Y, Toyama K, Honda A, Nakazaki K, Arai S, and Kurokawa M.
    J Infect Chemother. 2020 Feb;26(2):265-268.
  2. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy.
    Matsukawa T, Yamamoto T, Honda A, Toya T, Ishiura H, Mitsui J, Tanaka M, HaoA, Shinohara A, Ogura M, Kataoka K, Seo S, Kumano K, Hosoi M, Narukawa K, Yasunaga M, Maki H, Ichikawa M, Nannya Y, Imai Y, Takahashi T, Takahashi Y, Nagasako Y, Yasaka K, Koshi Mano K, Kawabe Matsukawa M, Miyagawa T, Hamada M, Sakuishi K, Hayashi T, Iwata A, Terao Y, Shimizu J, Goto J, Mori H, Kunimatsu A, Aoki S, Hayashi S, Nakamura F, Arai S, Momma K, Ogata K, Yoshida T, Abe O, Inazawa J, Toda T, Kurokawa M, and Tsuji S. Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy.
    Brain Commun. 2020 Jan 14;2(1):fcz048.
  3. The conserved and divergent roles of Prdm3 and Prdm16 in zebrafish and mouse craniofacial development.
    Shull LC, Sen R, Menzel J, Goyama S, Kurokawa M, and Artinger KB.
    Dev Biol. 2020 May 15;461(2):132-144.
  4. Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: A multicenter retrospective study.
    Takaoka K, Koya J, Yoshimi A, Toya T, Kobayashi T, Nannya Y, Nakazaki K, Arai S, Ueno H, Usuki K, Yamashita T, Imanishi D, Sato S, Suzuki K, Harada H, Manabe A, Hayashi Y, Miyazaki Y, and Kurokawa M.
    Leuk Lymphoma. 2020 Jul;61(7):1688-1694.
  5. Small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma of the dura mimicking tentorial meningioma.
    Hirano Y, Miyawaki S, Satou M, Taoka K, Toyama K, Ikemura M, Tanaka R, Takayanagi S, Tanaka S, Nakatomi H, Kurokawa K, and Saito N.
    World Neurosurg. 2020 Jun;138:169-173.
  6. Upfront surgery for small intestinal Non-Hodgkin’s Lymphoma.
    Iida T, Nozawa H, Sonoda H, Toyama K, Kawai K, Hata K, Tanaka T, Nishikawa T, Sasaki K, Shuno Y, Kaneko M, Murono K, Emoto S, Ishii H, Kurokawa M, and Ishihara S. Upfront surgery for small intestinal Non-Hodgkin’s Lymphoma.
    Anticancer Res. 2020 Apr;40(4):2373-2377.
  7. Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.
    Goyal G, Heaney M, Collin M, Aubart FC, Vaglio A, Durham B, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen E, Toyama K, Goodman A, Hendrie P, Cao X, Estrada-Veras J, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain K, Mazor R, Picarsic J, Janku F, Go R, Haroche J, and Diamond E.
    Blood. 2020 May 28;135(22):1929-1945.
  8. Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses.
    Matsuda K, Jo T, Miyauchi M, Toyama K, Nakazaki K, Matsui H, Fushimi K, Yasunaga H, and Kurokawa M.
    Leuk Lymphoma. 2020 Oct;61(10):2435-2441.
  9. The first case of concomitant Mycobacterium genavense lymphadenitis and EBV-positive lymphoproliferative disorder.
    Ito Y, Takaoka K, Toyama K, Wakabayashi Y, Shinozaki-Ushiku A, Okazaki A, Chikamatsu K, Mitarai S, Ushiku T, and Kurokawa M.
    Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020035.
  10. Insulin- and lipopolysaccharide-mediated signaling in adipose tissue macrophages regulates postprandial glycemia through Akt-mTOR activation.
    Toda G, Soeda K, Okazaki Y, Kobayashi N, Masuda Y, Arakawa N, Suwanai H,1 Masamoto Y, Izumida Y, Kamei N, Sasako T, Suzuki R, Kubota T, Kubota N, Kurokawa M, Tobe K, Noda T, Honda K, Accili D, Yamauchi T, Kadowaki T, and Ueki K.
    Mol Cell. 2020 Jul 2;79(1):43-53.e4.
  11. Fluoroquinolones for BK viral complication after transplantation: Meta-analysis.
    Ito Y, Hino T, Honda A, and Kurokawa M.
    Transplant Infectious Disease 22(6): e13433, 2020.
  12. Time trends in disseminated intravascular coagulation in Japan.
    Kurokawa M.
    JMA J. 2020 Oct 15;3(4):355-356.
  13. Underlying disease and clinical phenotypes of disseminated intravascular coagulation.
    Matsuda K and KurokawaM.
    JMA J. 2020 Oct 15;3(4):357-358.
  14. PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response.
    Ye J, Huang A, Wang H, Zhang AMY, Huang X, Lan Q, Sato T, Goyama S, Kurokawa M, Deng C, Sander M, Schaeffer DF, Li W, Kopp JL, Xie R.
    Cell Death Dis. 2020 Mar 16;11(3):187.
  15. Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells.
    Noura M, Morita K, Kiyose H, Matsuo H, Nishinaka-Arai Y, Kurokawa M, Kamikubo Y, Adachi S.
    Sci Rep. 2020 Nov 20;10(1):20245.
  16. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
    Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, Katsuto T, Miyamoto T, Morishige S, Hirokawa M, Fukuda T, Atsuta Y, Suzuki R.
    Hematol Oncol. 2020 Aug;38(3):266-271.
  17. A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors.
    Yokoyama Y, Maie K, Fukuda T, Uchida N, Mukae J, Sawa M, Kubo K, Kurokawa M, Nakamae H, Ichinohe T, Atsuta Y, Chiba S.
    Bone Marrow Transplant. 2020 Sep;55(9):1726-1735.
  18. Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group.
    Shinohara A, Oshima K, Fuji S, Umeda K, Kako S, Kurokawa M, Tsukada N, Kasai M, Kondo T, Hashii Y, Nakamae H, Ikegame K, Kosaka Y, Shimada A, Nawa Y, Makoto Y, Yoshiko A, Fukuda T, Tanaka J, Ogata M.
    Biol Blood Marrow Transplant. 2020 Jan;26(1):66-75.
  19. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.
    Watanabe K, Kage H, Nagoshi S, Toyama K, Ohno Y, Shinozaki-Ushiku A, Nakazaki K, Suzuki H, Kurokawa M, Nagase T.
    Case Rep Oncol Med. 2020 Mar 19;2020:4201727.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2019年

  1. Ito Y, Miyauchi M, Nakamura T, Takahara N, Nakai Y, Taoka K, Toyama K, Shinozaki-Ushiku A, Koike K, Kurokawa M.
    Significance of biopsy with ERCP for diagnosis of bile duct invasion of DLBCL. Int J Hematol.
    2019 Sep;110(3):381-384.
  2. Takaoka K, Koya J, Yoshimi A, Toya T, Kobayashi T, Nannya Y, Nakazaki K, Arai S, Ueno H, Usuki K, Yamashita T, Imanishi D, Sato S, Suzuki K, Harada H, Manabe A, Hayashi Y, Miyazaki Y, Kurokawa M.
    Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study.
    Leuk Lymphoma. 2020 Mar 11:1-7. doi: 10.1080/10428194.2020.1734595
  3. Sasaki K, Miyauchi M, Ogura M, Shimura-Nukina A, Toyama K, Nakazaki K, Watadani T, Abe O, Kurokawa M.
    Arteritis after administration of granulocyte colony-stimulating factor: a case series.
    Int J Hematol. 2019 Sep;110(3):370-374. doi: 10.1007/s12185-019-02662-6. Epub 2019 May 14
  4. Ebisawa K, Masamoto Y, Koya J, Shimura A, Shinozaki-Ushiku A, Toyama K, Nakazaki K, and Kurokawa M.
    Long-term remission by brentuximab vedotin for non-mediastinal gray zone lymphoma refractory to autologous stem cell transplantation.
    Clinical Lymphoma, Myeloma and Leukemia 19(11): e602-e604, 2019.
  5. Ebisawa K, Masamoto Y, Tokushige J, Nishi H, Honda K, Hinata M, Toyama K, Nangaku M, Kurokawa M.
    Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
    Annals of Hematology. [in press]
    PMID: 30761408
  6. Takaoka K, Kawazu M, Koya J, Yoshimi A, Masamoto Y, Maki H, Toya T, Kobayashi T, Nannya Y, Arai S, Ueno T, Ueno H, Suzuki K, Harada H, Manabe A, Hayashi Y, Mano H, Kurokawa M.
    A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.
    Leukemia. [in press]
    PMID: 30696947
  7. Matsuda K, Koya J, Arai S, Nakazaki K, Nakamura F, Kurokawa M.
    Cyclosporine Therapy in Patients with Transfusion-independent Non-severe Aplastic Anemia: A Retrospective Analysis.
    Intern Med. 58(3):355-360, 2019.
    PMID: 30146592
  8. Matsuda K, Honda A, Arai S, Maki H, Nakazaki K, Kurokawa M.
    Retrospective analysis on transient recurrence of steroid-sensitive acute graft-versus-host disease.
    Bone Marrow Transplant. 54(2):316-319, 2019.
    PMID: 30108328
  9. Uni M, Masamoto Y, Sato T, Kamikubo Y, Arai S, Hara E, Kurokawa M.
    Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
    Leukemia. 33(1):191-204, 2019.
    PMID: 29967380

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2018年

  1. Uni M, Kurokawa M.
    Role of ASXL1 mutation in impaired hematopoiesis and cellular senescence.
    Oncotarget. 9(96):36828-36829, 2018
    PMID: 30627322
  2. Taoka K, Arai S, Kataoka K, Hosoi M, Miyauchi M, Yamazaki S, Honda A, Aixinjueluo W, Kobayashi T, Kumano K, Yoshimi A, Otsu M, Niwa A, Nakahata T, Nakauchi H, Kurokawa M.
    Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.
    Scientific Reports. 8(1):15855, 2018.
    PMID: 30367142
  3. Ebisawa K, Koya J, Nakazaki K, Arai S, Nakamura F, Kurokawa M.
    Usefulness of presepsin for early detection of infections in patients with hematologic disorders.
    Clin Chim Acta. 486:374-380, 2018.
    PMID: 30144441
  4. Chiba A, Toya T, Mizuno H, Tokushige J, Nakamura F, Nakazaki K, Kurokawa M.
    Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
    Int J Hematol. 108(6):640-646, 2018.
    PMID: 30078165
  5. Toya T, Ogura M, Toyama K, Yoshimi A, Shinozaki-Ushiku A, Honda A, Honda K, Hosoya N, Murakami Y, Kawashima H, Nannya Y, Arai S, Nakamura F, Shinoda Y, Nangaku M, Miyagawa K, Fukayama M, Moriya-Saito A, Katayama I, Ogura T, Kurokawa M.
    Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.
    Haematologica. 103(11):1815-1824, 2018.
    PMID: 29976744
  6. Koya J, Kurokawa M.
    Functional role of DNMT3A mutation in acute myeloid leukemia.
    Rinsho Ketsueki. 59(5):602-610, 2018.
    PMID: 29877252
  7. Suzuki Y, Honda A, Nakazaki K, Mizuno H, Ikemura M, Shinozaki-Ushiku A, Nakamura F, Fukayama M, Kurokawa M.
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Annals of Hematology. 97(7):1297-1298, 2018.
    PMID: 29582109
  8. Masamoto Y, Kurokawa M.
    Targeting chronic myeloid leukemia stem cells with prostaglandin E1.
    Stem Cell Investigation. 5:10, 2018
    PMID: 29780814
  9. Yasunaga M, Taoka K, Nakagawa H, Yamada A, Abe H, Nakazaki K, Fukayama M, Koike K, Kurokawa M.
    Eculizumab treatment for ischemic enteritis accompanied with paroxysmal nocturnal hemoglobinuria: a case report and literature review.
    Annals of Hematology. 97(8):1513-1515, 2018.
    PMID: 29532162
  10. Morita K, Koya J, Toya T, Nakamura F, Kurokawa M.
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia; a case report and literature review.
    Annals of Hematology. 97(6):1105-1109, 2018
    PMID: 29404721
  11. Suzuki Y, Koya J, Ebisawa K, Abe H, Shinozaki-Ushiku A, Nakamura F, Kurokawa M.
    Sequential development of monoclonal B-cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Annals of Hematology. 97(5): 917-919, 2018.
    PMID: 29417202
  12. Miyauchi M, Koya J, Arai S, Yamazaki S, Honda A, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M.
    ADM8 is an antigen of TKI-resistant CML cells identified by patient-derived induced pluripotent stem cells.
    Stem Cell Reports. 10(3): 1115-1130, 2018.
    PMID: 29429960
  13. Toyama K, Yasumoto A, Nakamura F, Arai S, Kurokawa M.
    The development of acute systemic multiple thrombosis after the remission during systemic glucocorticoid therapy for acquired hemophilia A.
    Intern Med. 57(15):2237-2241, 2018.
    PMID: 29526954
  14. Morita K, Honda A, Koya J, Toyama K, Ikeda M, Misawa Y, Okugawa S, Nakamura F, Moriya K, Kurokawa M.
    Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
    J Infect Chemother. 24(7):576-578.
    PMID: 29371065
  15. Maki H, Nannya Y, Imai Y, Yamaguchi S, Kamikubo Y, Ichikawa M, Nakamura F,　Kurokawa M.
    Nonmyelomatous ascites resulting from increased secretion of vascular　endothelial growth factor in multiple myeloma.
    Intern Med. 57(5):725-727, 2018
    PMID: 29151500
  16. Matsuda K, Toyama K, Toya T, Ikemura M, Nakamura F, Kuromawa M.
    Reactivation of hemophagocytic lymphohistiocytosis triggered by antithymocyte globulin.
    Intern Med. 57(4):583-586, 2018.
    PMID: 29225252

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2017年

  1. Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes.
    A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
    Am J Hematol. 92:1324-1332, 2017.
    PMID: 28891083
  2. Matsuda K, Taoka K, Jona M, Masuda A, Arai S, Nakamura F, Yatomi Y, Kurokawa M.
    Clinical features of hematological disorders with increased large granular lymphocytes (LGLs): A retrospective study.
    Annals of Hematology. 96:2113-2115, 2017.
    PMID: 29098369
  3. Matsuda K, Koya J, Toyama K, Ikeda M, Arai S, Nakamura F, Okugawa S, Moriya K, Kurokawa M.
    A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
    J Infect Chemother. 23:788-790, 2017
    PMID: 28743428
  4. Chiba A, Nakamura F, Nakazaki K, Kurokawa M.
    Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
    Leuk Lymphoma. 12:1-3, 2017
    PMID: 28697686
  5. Masamoto Y, Arai S, Sato T, Kubota N, Takamoto I, Kadowaki T, Kurokawa M.
    Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation.
    Stem Cells. 35(7):1835-1848, 2017
    PMID: 28480607
  6. Koya J, Ibaraki T, Yamazaki I, Nakamura F, Kurokawa M.
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 96(7):1197-1199, 2017
    PMID: 28424883
  7. Mizuno H, Koya J, Fujioka Y, Ibaraki T, Nakamura F, Hayashi A, Shinozaki-Ushiku A, Akamatsu N, Hasegawa K, Kokudo N, Fukuyama M, Kurokawa M.
    Extranodal NK/T cell lymphoma in a living donor liver transplant recipient.
    Ann Hematol. 96(6):1051-1052, 2017
    PMID: 28280996
  8. Morita K, Nakamura F, Sakuishi K, Yamamoto T, Shimizu J, Tsuji S, Kurokawa M.
    Successful management of chronic myeloid leukemia with a complication of anti-SRP antibody-associated myopathy.
    Leuk Lymphoma. 58(5):1242-1245, 2017
    PMID: 27724131

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2016年

  1. Masamoto Y, Kurokawa M.
    Inflammation-induced emergency megakaryopoiesis: inflammation paves the way for platelets.
    Stem Cell Investig 3:16, 2016.
    PMID: 27486586
  2. Sumitomo Y, Koya J, Nakazaki K, Kataoka K, Tsuruta-Kishino T, Morita K, Sato T, Kurokawa M.
    Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Blood 128(12):1614-24, 2016.
    PMID: 27480114
  3. Koya J, Kataoka K, Sato T, Bando M, Kato Y, Tsuruta-Kishino T, Kobayashi H, Narukawa K, Miyoshi H, Shirahige K, and Kurokawa M.
    DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.
    Nat Commun 7:10924, 2016.
    PMID: 27010239
  4. Masamoto Y, Arai S, Sato T, Yoshimi A, Kubota N, Takamoto I, Iwakura Y, Yoshimura A, Kadowaki T, and Kurokawa M.
    Adiponectin enhances antibacterial activity of hematopoietic cells by suppressing bone marrow inflammation.
    Immunity 44(6):1422-33, 2016.
    PMID: 27317261
  5. Ebisawa K, Koya J, Shinozaki-Ushiku A, Nakamura F, and Kurokawa M.
    Paraneoplastic limbic encephalitis in B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and classical Hodgkin lymphoma.
    Ann Hematol 95(6):1011-2, 2016.
    PMID: 26984106
  6. Morita K, Nakamura F, Taoka K, Satoh Y, Iizuka H, Masuda A, Seo S, Nannya Y, Yatomi Y, and Kurokawa M.
    Incidentally-detected t(9;22)(q34;q11)/BCR-ABL1- positive clone developing into chronic phase chronic myeloid leukaemia after four years of dormancy.
    Br J Haematol 174(5):815-7, 2016.
    PMID: 26560179
  7. Nakamura F, Nakamura F, Ikemura M, Fukayama M, and Kurokawa M.
    Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma.
    Ann Hematol 95(10):1733-5, 2016.
    PMID: 26884589
  8. Shinohara A, Honda A, Nukina A, Takaoka K, Tsukamoto A, Hangai S, Kogure Y, Kobayashi T, Yamazaki S, Ueda K, Nakamura F, Nannya Y, and Kurokawa M.
    Acute pericarditis before engraftment in hematopoietic stem cell transplantation.
    Bone Marrow Transplant 51(3):459-61, 2016.
    PMID: 26595074
  9. Toya T, Nannya Y, Hangaishi A, Shiseki M, Shimoyama T, Sakamaki H, Motoji T, Usuki K, Nakamura F, and Kurokawa M.
    Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
    Leuk Lymphoma 57(4):961-4, 2016.
    PMID: 26366623
  10. Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, and Kurokawa M.
    Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.
    Ann Oncol 27(5):887-95, 2016.
    PMID: 26884589

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2015年

  1. Arai S, Miyauchi M, and Kurokawa M.
    Modeling of hematologic malignancies by iPS technology.
    Exp Hematol 43(8):654-60, 2015.
    PMID: 26135030
  2. Hangai S, Nannya Y, and Kurokawa M.
    Role of procalcitonin and C-reactive protein for discrimination between tumor fever and infection in patients with hematological diseases.
    Leuk Lymphoma 56: 910-4, 2015.
    PMID: 24991721
  3. Higo T, Miyagaki T, Nakamura F, Shinohara A, Asano H, Abe H, Senda N, Yoshizaki A, Fukayama M, and Kurokawa M.
    Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
    Ann Hematol 94: 683-5, 2015.
    PMID: 25199505
  4. Higo T, Kobayashi T, Yamazaki S, Ando S, Gonoi W, Ishida M, Okuma H, Nakamura F, Ushiku T, Ohtomo K, Fukayama M, and Kurokawa M.
    Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia.
    Int J Clin Exp Pathol 8(10):13639-42, 2015.
    PMID: 26722589
  5. Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, and Kurokawa M.
    Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
    Exp Hematol 43(10):849-57, 2015.
    PMID: 26021490
  6. Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F, and Kurokawa M.
    Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
    Ann Hematol 94: 989-94, 2015.
    PMID: 25687839
  7. Morita K, Masamoto Y, Kataoka K, Koya J, Kagoya Y, Yashiroda H, Sato T, Murata S, and Kurokawa M.
    BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
    Leukemia 29(11):2248-56, 2015.
    PMID: 26050649
  8. Nasu R, Nannya Y, and Kurokawa M.
    A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies.
    Int J Hematol 101: 376-85, 2015.
    PMID: 25644148
  9. Uni M, Shinohara A, Nukina A, Nakamura F, Nannya Y, Mizoguchi M, Okazaki M, Tatsuno K, Moriya K, and Kurokawa M.
    Successful management of Rothia aeria pneumonia during the peritransplant period: first reported case in allogeneic hematopoietic stem cell transplant.
    Leuk Lymphoma 56: 248-50, 2015.
    PMID: 24766467
  10. Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, and Kurokawa M.
    Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia.
    Jpn J Clin Oncol 45: 745-8, 2015.
    PMID: 25644148
  11. Uni M, Kagoya Y, Nannya Y, Nakamura F, and Kurokawa M.
    Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors.
    Leuk Lymphoma 56: 1869-71, 2015.
    PMID: 25267182

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2014年

  1. Hangai S, Yoshimi A, Hosoi A, Matsusaka K, Ichikawa M, Fukayama M, and Kurokawa M.
    An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production.
    Int J Hematol 99: 523-6, 2014.
    PMID: 24481938
  2. Harada S, Yamazaki S, Nakamura F, Morita K, Yoshimi A, Shinozaki-Ushiku A, Fukayama M, and Kurokawa M.
    Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination.
    Int J Clin Exp Pathol 7: 6386-90, 2014.
    PMID: 25337296
  3. Honda A, Nakamura F, Nannya Y, Shintani Y, Fukayama M, Ichikawa M, and Kurokawa M.
    Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Ann Hematol 93: 1073-4, 2014.
    PMID: 24173088
  4. Honda A, Yoshimi A, Ushiku T, Shinoda Y, Kawano H, Toya T, Kogure Y, Yamashita H, Kume H, Nannya Y, and Kurokawa M.
    Successful control of carcinoma of unknown primary with axitinib, a novel molecular-targeted agent: a case report.
    Chemotherapy 60(5-6):342-5, 2014.
    PMID: 26288144
  5. Hosoi M, Kumano K, Taoka K, Arai S, Kataoka K, Ueda K, Kamikubo Y, Takayama N, Otsu M, Eto K, Nakauchi H, and Kurokawa M.
    Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples.
    Exp Hematol 42: 816-25, 2014.
    PMID: 24859480
  6. Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y, and Kurokawa M.
    NF-κB/TNF-α positive feedback loop with active proteasome machinery supports myeloid leukemia initiating cell capacity.
    J Clin Invest 124:528-42, 2014.
    PMID: 24382349
  7. Kagoya Y, Yoshimi A, Tsuruta-Kishino T, Arai S, Satoh T, Akira S, and Kurokawa M.
    JAK2V617F-positive myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.
    Blood 124: 2996-3006, 2014.
    PMID: 25217696
  8. Kagoya Y, Nannya Y, Nakamura F, and Kurokawa M.
    Gene expression profiles of central nervous system lymphoma predict poor survival in patients with diffuse large B-cell lymphoma.
    Br J Haematol 166: 794-7, 2014.
    PMID: 24749697
  9. Kobayashi T, Seo S, Morita S, Goto A, Masuda A, Shimizu N, Nishida M, Nunobe S, Ichikawa M, Takazawa Y, Seto Y, Fukayama M, and Kurokawa M.
    Esophageal intramucosal hematoma after peripheral blood stem cell transplantation: case report and review of literature.
    Int J Clin Exp Pathol 7: 2690-4, 2014.
    PMID: 24966988
  10. Kogure Y, Nakamura F, Nukina A, Kamikubo Y, Ichikawa M, Kamikubo Y, and Kurokawa M.
    Catheter-related septic shock by Micrococcus in an autologous hematopoietic stem cell transplantation recipient.
    Am J Infect Control 42: 87, 2014.
    PMID: 24388476
  11. Kogure Y, Nakamura F, Shinozaki-Ushiku A, Watanabe A, Kamei K, Yoshizato T, Nannya Y, Fukayama M, and Kurokawa M.
    Pulmonary mucormycosis with embolism: two autopsied cases of acute myeloid leukemia.
    Int J Clin Exp Pathol 7: 3449-53, 2014.
    PMID: 25031775
  12. Nakazaki K, Nannya Y, and Kurokawa M.
    Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
    Int J Hematol 99: 53-6, 2014.
    PMID: 24307517
  13. Nannya Y, Shinohara A, Ichikawa M, and Kurokawa M.
    Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation.
    Biol Blood Marrow Transplant 20: 430-4, 2014.
    PMID: 24333749
  14. Nasu R, Nannya Y, Shinohara A, Ichikawa M, and Kurokawa M.
    Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
    Ann Hematol 93: 1215-23, 2014.
    PMID: 24590535
  15. Nishikawa S, Arai S, Masamoto Y, Kagoya Y, Toya T, Watanabe-Okochi N, and Kurokawa M.
    Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
    Blood 124: 3587-96, 2014.
    PMID: 25298035
  16. Nukina A, Kagoya Y, Watanabe-Okochi N, Arai S, Ueda K, Yoshimi A, Nannya Y, and Kurokawa M.
    Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia.
    Br J Haematol 165: 414-6, 2014.
    PMID: 24401018
  17. Ogura M, Ichikawa M, Masuda A, Kandabashi K, Nannya Y, and Kurokawa M.
    A mixed-type autoimmune hemolytic anemia with immune thrombocytopenia related with myositis and post-transplantation lymphoproliferative disorder.
    Ann Hematol 93: 869-71, 2014.
    PMID: 24013519
  18. Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, and Kurokawa M.
    Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Oncogene 33: 5028-38, 2014.
    PMID: 24747972
  19. Satoh Y, Masuda A, Jona M, Nannya Y, Yokota H, Kurokawa M, and Yatomi Y.
    Heparin-mediated inhibition of PCR in the accelerated phase of chronic myeloid leukaemia characterized by abundant basophilia.
    Eur J Haematol 92: 456-7, 2014.
    PMID: 24373003
  20. Shinohara A, Imai Y, Nakagawa M, Takahashi T, Ichikawa M, and Kurokawa M.
    Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors.
    Stem Cells 32: 548-57, 2014.
  21. Takaoka K, Nannya Y, Shinohara A, Arai S, Nakamura F, and Kurokawa M.
    A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma.
    Ann Hematol 93: 1637-44, 2014.
    PMID: 24908330
  22. Toya T, Yoshimi A, Morioka T, Arai S, Ichikawa M, Usuki K, and Kurokawa M.
    Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia.
    Platelets 25: 300-2, 2014.
    PMID: 23971860
  23. Tsukamoto A, Nakamura F, Nannya Y, Kobayashi Y, Shibahara J, Ichikawa M, Fukayama M, Koike K, and Kurokawa M.
    MALT lymphoma of the small bowel with protein-losing enteropathy.
    Int J Hematol.
    99: 198-201, 2014.
    PMID: 24395281
  24. Tsukamoto A, Yoshiki Y, Yamazaki S, Kumano K, Nakamura F, and Kurokawa M.
    The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion.
    Ann Hematol 93: 507-8, 2014.
    PMID: 23797638
  25. Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, and Kurokawa M.
    Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
    Cancer Sci 105: 512-9, 2014.
    PMID: 24612037
  26. Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, and Kurokawa M.
    Safety of high-dose micafungin for patients with hematological diseases.
    Leuk Lymphoma 55: 2572-6, 2014.
    PMID: 24460099
  27. Yoshimi A, Toya T, Kawazu M, Ueno T, Tsukamoto T, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, and Kurokawa M.
    Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
    Nature Commun 5: 4770, 2014.
    PMID: 25159113

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2013年

  1. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, and Mulloy JC.
    Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
    J Clin Invest 123: 3876-88, 2013.
  2. Hangai S, Nakamura F, Kamikubo Y, Honda A, Arai S, Nakagawa M, Ichikawa M, and Kurokawa M.
    Erythroleukemia showing early erythroid and cytogenetic responses to azacitidine therapy.
    Ann Hematol 92: 707-9, 2013.
  3. Hangai S, Nakamura F, Kamikubo Y, Ichikawa M, Suzuki H, Yoshida S, Yamada A, Takazawa Y, Fukayama M, Koike K, and Kurokawa M.
    Primary gastrointestinal follicular lymphoma with histological transformation.
    Ann Hematol 92: 993-4, 2013.
  4. Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, and Kurokawa M.
    A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Int J Hematol 97: 726-34, 2013.
  5. Kobayashi T, Ichikawa M, Kamikubo Y, and Kurokawa M.
    Acute myeloid leukemia with cryptic CBFB-MYH11 type D.
    Int J Clin Exp Pathol 6: 110-2, 2013.
  6. Kobayashi T, Hangaishi A, Yamamoto G, Shinohara A, Morikawa T, Takazawa Y, Ota S, Imai Y, Nakamura F, and Kurokawa M.
    Successful treatment of secondary NK/T-cell lymphoma of the testis.
    Ann Hematol 92: 997-8, 2013.
  7. Kobayashi T, Ichikawa M, Nannya Y, and Kurokawa M.
    The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
    Jpn J Clin Oncol 43: 1047-51, 2013.
  8. Koya J, Nannya Y, Kobayashi H, Okugawa S, Moriya K, and Kurokawa M.
    Simultaneous increase in 1,3-β-D-glucan and procalcitonin levels in Pseudomonas aeruginosa infection.
    J Infect 67: 164-6, 2013.
  9. Kumano K, Arai S, and Kurokawa M.
    Generation of iPS cells from normal and malignant hematopoietic cells.
    Int J Hematol 98: 145-52, 2013.
  10. Morita K, Nannya Y, Yoshizato T, and Kurokawa M.
    Simple but powerful prognostic scoring model for MALT lymphoma: a retrospective study.
    Ann Hematol 92: 421-3, 2013.
  11. Morita K, Yoshimi A, Masuda A, Ichikawa M, Yatomi Y, and Kurokawa M.
    Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
    Int J Hematol 98: 247-9, 2013.
  12. Shinohara A, Yoshiki Y, Masamoto Y, Hangaishi A, Nannya Y, and Kurokawa M.
    Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
    Leuk Lymphoma 54: 794-8, 2013.
  13. Toya T, Shinohara A, Tatsuno K, Seo S, Nannya Y, Ichikawa M, Makimura K, Moriya K, and Kurokawa M.
    A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia.
    Int J Hematol 98: 261-3, 2013.
  14. Uni M, Yoshimi A, Nakamura F, Takazawa Y, Fukayama M, and Kurokawa M.
    Successful allogeneic stem cell transplantation for Lennert lymphoma.
    Ann Hematol 92: 859-60, 2013.
  15. Uni M, Yoshimi A, Maki H, Maeda D, Nakazaki K, Nakamura F, Fukayama M, and Kurokawa M.
    Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation.
    Int J Clin Exp Pathol 6: 1190-4, 2013.
  16. Uni M, Nakamura F, Yoshimi A, Shinozaki-Ushiku A, Hosoi A, Nakazaki K, Nannya Y, Fukayama M, and Kurokawa M.
    Transformation of follicular lymphoma in the retroperitoneal muscles demonstrated by CT-guided needle biopsy of FDG-avid lesions: case series.
    Int J Clin Exp Pathol 15: 402-6, 2013.
    PMID: 24427363
  17. Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, and Kurokawa M.
    The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
    Blood 121: 4142-55, 2013.
  18. Yoshizato T, Nannya Y, Imai Y, Ichikawa M, and Kurokawa M.
    Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma.
    Clin Lymphoma Myeloma Leuk 13: 410-6, 2013.
  19. Yoshizato T, Watanabe-Okochi N, Nannya Y, Ichikawa M, Takahashi T, Sato T, Masuda A, Yatomi Y, Tsuno NH, Kurokawa M, and Takahashi K.
    Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors.
    Int J Hematol 98: 56-65, 2013.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2012年

  1. Fujioka Y, and Kurokawa M.
    Follicular lymphoma presenting with massive splenomegaly.
    Int J Hematol 95: 3-4, 2012.
  2. Goyama S, Takeuchi K, Kanda Y, Nannya Y, Chiba S, Fukayama M, and Kurokawa M.
    Post-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study.
    Bone Marrow Transplant 47: 1243-5, 2012.
  3. Hangai S, Nakamura F, Yamada A, Watabe H, Ichikawa M, Koike K, and Kurokawa M.
    Usefulness of double-balloon enteroscopy for evaluation of duodenal follicular lymphoma.
    Ann Hematol 91: 1819-20, 2012.
  4. Kagoya Y, Nannya Y, and Kurokawa M.
    Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
    Leuk Res 36: 1016-21, 2012.
  5. Kagoya Y, Seo S, Nannya Y, and Kurokawa M.
    Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.
    Clin Transplant 26: E168-75, 2012.
  6. Kataoka K, and Kurokawa M.
    Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.
    Cancer Sci 103: 1371-7, 2012.
  7. Koya J, Iwata A, Nakamura F, Nagashima Y, Ichikawa M, Tsuji S, and Kurokawa M.
    Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.
    J Neurol Sci 315: 150-2, 2012.
  8. Koya J, Nannya Y, Ichikawa M, and Kurokawa M.
    The clinical role of procalcitonin in hematopoietic SCT.
    Bone Marrow Transplant 47: 1326-31, 2012.
  9. Koya J, Nannya Y, and Kurokawa M.
    Evaluation of procalcitonin with liquid-phase binding assay in hematological malignancy.
    Clin Chim Acta 413: 1633-6, 2012.
  10. Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, Otsu M, Nagae G, Ueda K, Nakazaki K, Kamikubo Y, Eto K, Aburatani H, Nakauchi H, and Kurokawa M.
    Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
    Blood 119: 6234-42, 2012.
  11. Miyauchi M, Yoshimi A, Nannya Y, Takazawa Y, Ichikawa M, Fukayama M, and Kurokawa M.
    Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation.
    Int J Hematol 96: 146-8, 2012.
  12. Morita K, Nakamura F, Kamikubo Y, Mizuno N, Miyauchi M, Yamamoto G, Nannya Y, Ichikawa M, and Kurokawa M.
    Pituitary lymphoma developing within pituitary adenoma.
    Int J Hematol 95: 721-4, 2012.
  13. Morita K, Nakamura F, Nannya Y, Kamikubo Y, Ichikawa M, and Kurokawa M.
    Lymphoma with specific affinity to endocrine organs.
    Ann Hematol 91: 1149-50, 2012.
  14. Morita K, Nakamura F, Nannya Y, Nomiya A, Arai S, Ichikawa M, Maeda D, Homma Y, and Kurokawa M.
    Primary MALT lymphoma of the urinary bladder in the background of interstitial cystitis.
    Ann Hematol 91: 1505-6, 2012.
  15. Nakazaki K, Hosoi M, Hangaishi A, Ichikawa M, Nannya Y, and Kurokawa M.
    Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study.
    Intern Med 51: 859-63, 2012.
  16. Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, and Kurokawa M.
    The effect of iron overload and chelation on erythroid differentiation.
    Int J Hematol 95: 149-59, 2012.
  17. Taoka K, Yamamoto G, Kaburaki T, Takahashi T, Araie M, and Kurokawa M.
    Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy.
    Br J Haematol 157: 252-4, 2012.
  18. Toya T, Nannya Y, Narukawa K, Ichikawa M, and Kurokawa M.
    A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
    Jpn J Infect Dis 65: 228-32, 2012.
  19. Toya T, Nishimoto N, Koya J, Nakagawa M, Nakamura F, Kandabashi K, Yamamoto G, Nannya Y, Ichikawa M, and Kurokawa M.
    The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement.
    Leuk Res 36: 117-8, 2012.
  20. Yamamoto G, Hosoi M, Miyagawa T, Ohmatsu H, Ichikawa M, Sugaya M, and Kurokawa M.
    Evans syndrome with cytomegalovirus infection followed by emerging peripheral T-cell lymphoma.
    Ann Hematol 91: 123-4, 2012.
  21. Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, and Kurokawa M.
    Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
    Intern Med 51: 3427-30, 2012.
  22. Yoshiki Y, Yamamoto G, Takazawa Y, Nannya Y, Ishida J, Nagai R, Fukayama M, and Kurokawa M.
    AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis.
    Ann Hematol 91: 467-8, 2012.
  23. Yoshimi A, Yamamoto G, Goto T, Koike K, and Kurokawa M.
    Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease.
    Ann Hematol 91: 1501-2, 2012.
  24. Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, and Kurokawa M.
    Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation.
    Eur J Immunol 42: 1044-50, 2012.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年

2011年

  1. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, and Kurokawa M.
    Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
    Blood 117: 6304-14, 2011.
  2. Kagoya Y, Kataoka K, Nannya Y, and Kurokawa M.
    Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation.
    Biol Blood Marrow Transplant 17: 394-400, 2011.
  3. Kagoya Y, Takahashi T, Nannya Y, Shinozaki A, Ota S, Fukayama M, and Kurokawa M.
    Hyperbilirubinemia after hematopoietic stem cell transplantation: comparison of clinical and pathologic findings in 41 autopsied cases.
    Clin Transplant 25: E552-7, 2011.
  4. Kagoya Y, Takahashi T, Yoshimoto T, Ichikawa M, Hangaishi A, Fukayama M, and Kurokawa M.
    Recurrent pericardial effusion after treatment for primary effusion lymphoma-like lymphoma: an autopsied case.
    Ann Hematol 90: 219-20, 2011.
  5. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T, and Kurokawa M.
    Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.
    J Exp Med 208: 2403-16, 2011.
  6. Kobayashi CI, Yamamoto G, Hayashi A, Ota S, Imai Y, Fukayama M, and Kurokawa M.
    Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma.
    Ann Hematol 90: 225-6, 2011.
  7. Kobayashi H, Ichikawa M, Hangaishi A, Imai Y, and Kurokawa M.
    Concurrent development of "Burkitt-like" lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin.
    Int J Hematol 93: 112-7, 2011.
  8. Koya J, Nannya Y, Yoshizato T, Ono K, Seo S, Nakagawa M, Ichikawa M, and Kurokawa M.
    Disseminated tuberculosis following unrelated cord blood transplantation for refractory peripheral T-cell lymphoma: Clinical role of serum procalcitonin levels.
    J Infect 62: 237-40, 2011.
  9. Masamoto Y, Nannya Y, and Kurokawa M.
    Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature.
    J Chemother 23: 17-23, 2011.
  10. Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, and Kurokawa M.
    AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
    Blood 118: 6626-37, 2011.
  11. Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, and Kurokawa M.
    The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk.
    Transpl Int 24: 469-76, 2011.
  12. Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, Takahashi T, Kamikubo Y, Imai Y, and Kurokawa M.
    Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.
    Blood 118: 2541-50, 2011.
  13. Ogura M, Todo T, Tanaka M, Nannya Y, Ichikawa M, Nakamura F, and Kurokawa M.
    Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
    Br J Haematol 154: 663-5, 2011.
  14. Seo S, Nakamoto T, Takeshita M, Lu J, Sato T, Suzuki T, Kamikubo Y, Ichikawa M, Noda M, Ogawa S, Honda H, Oda H, and Kurokawa M.
    Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Cancer Sci 102: 2109-17, 2011.
  15. Yamamoto G, Maki H, Ichikawa M, and Kurokawa M.
    Pure red cell aplasia with follicular lymphoma showing regression and progression parallel to lymphoma.
    Int J Hematol 94: 576-7, 2011.
  16. Yamazaki S, Fujioka Y, Nakamura F, Ota S, Shinozaki A, Yamamoto G, Kamikubo Y, Nannya Y, Ichikawa M, Fukayama M, and Kurokawa M.
    Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Pathol Int 61: 662-6, 2011.
  17. Yamazaki S, Nakamura F, Nasu R, Nannya Y, Ichikawa M, and Kurokawa M.
    Haemophagocytic lymphohistiocytosis is a recurrent and specific complication of acute erythroid leukaemia.
    Br J Haematol 153: 669-72, 2011.
  18. Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, Takahashi T, and Kurokawa M.
    A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
    Intern Med 50: 2649-52, 2011.
  19. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, and Kurokawa M.
    Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Blood 117: 3617-28, 2011.
  20. Yoshimi A, and Kurokawa M.
    Evi1 forms a bridge between the epigenetic machinery and signaling pathways.
    Oncotarget 2: 575-86, 2011.
  21. Yoshimi A, and Kurokawa M.
    Key roles of histone methyltransferase and demethylase in leukemogenesis.
    J Cell Biochem 112: 415-24, 2011.
  22. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, and Kurokawa M.
    Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
    Int J Hematol 93: 400-2, 2011.

2023年 2022年 2021年 2020年 2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年